Nasal spray could tame tough asthma Flare-Ups
NCT ID NCT07250594
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests AD17002, a nasal spray that aims to calm the immune system in people with moderate to severe eosinophilic asthma that is not well controlled by current treatments. About 126 adults will receive either the spray or a placebo for 3 months. Researchers will check if it reduces asthma attacks and is safe to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AD17002 (an intranasal immunomodulator)
- What this could lead to
- If successful, this could provide a new add-on treatment option to better control moderate to severe eosinophilic asthma and reduce flare-ups.
- What could go wrong
- This is an early Phase 2 trial with only 126 participants, so results may not confirm effectiveness. The treatment is an add-on, not a replacement for current asthma medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advagene Biopharma
Taipei, Taiwan, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart inhalers track Fasenra's asthma control over full dosing cycle
- Blood cell study may personalize asthma and sinusitis treatment
- Asthma Drug's gene secrets revealed in small study
- Proteomics may unlock key clues to mepolizumab success in rare lung disease
- New asthma pill shows promise in Mid-Stage trial
- Asthma drug trial halted midway: what it means for patients